Benchmark Holdings PLC Notice of Q2 and Interim Results (7967V)
April 19 2021 - 01:00AM
UK Regulatory
TIDMBMK
RNS Number : 7967V
Benchmark Holdings PLC
19 April 2021
19 April 2021
Benchmark Holdings plc
("Benchmark" or the "Company")
Notice of Q2 and Interim Results
Webcast for analysts and institutional investors
Equity Development webcast for retail investors
Benchmark Holdings plc (AIM: BMK), the aquaculture health,
advanced nutrition, and genetics business, will announce its Q2 and
Interim results for the three and six month periods ended 31 March
2021, on Tuesday 18 May 2021.
Webcast for analysts and institutional investors at 9am UK
time
Trond Williksen, Chief Executive Officer and Septima Maguire,
Chief Financial Officer will host a webcast for analysts and
institutional investors on that day at 09:00am UK time. To register
your interest, please contact benchmark@mhpc.com .
Equity Development webcast for retail investors at 12:30pm UK
time
Trond Williksen, Chief Executive Officer and Septima Maguire,
Chief Financial Officer will host a separate webcast for retail
investors and wealth managers at 12.30pm UK time. The webcast is
open to all existing and potential shareholders. Questions can be
submitted during the presentation which will be addressed at the
end.
To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-holdings-interim-results-investor-presentation-18th-may-2021
.
Enquiries
For further information, please contact:
Benchmark Holdings plc Tel: 020 3696 0630
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
James Black, Freddie Barnfield, Duncan
Monteith
MHP Communications Tel: 020 3128 8990
Katie Hunt, Reg Hoare, Alistair de Kare-Silver, benchmark@mhpc.com
Charlie Protheroe
Equity Development Tel: 020 7065 2690
Hannah Crowe
About Benchmark
Benchmark's mission is to enable aquaculture producers to
improve their sustainability and profitability.
We bring together biology and technology, to develop innovative
products which improve yield, quality and animal health and welfare
for our customers. We do this by improving the genetic make-up,
health and nutrition of their stock - from broodstock and hatchery
through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), diets and probiotics
and sea lice treatments. Find out more at www.benchmarkplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORIFMFTMTTBBPB
(END) Dow Jones Newswires
April 19, 2021 02:00 ET (06:00 GMT)
Benchmark (LSE:BMK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Benchmark (LSE:BMK)
Historical Stock Chart
From Mar 2023 to Mar 2024